$ B6 o3 n/ G) l, G临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: ) `* M% R3 h3 X( A5 aEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.# V, E0 s9 M& R B; j9 p( U2 k' r http://www.ncbi.nlm.nih.gov/pubmed/22968184& q# Q; z% U- ^& {7 J: l
1 O1 c* V/ ]1 j% G' F6 u! Z8 h
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制; S. s9 k. I+ n http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx